Download PDFPDF

Dexamethasone treatment and cerebral palsy
Compose Response

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g.
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Statement of Competing Interests


  • Responses are moderated before posting and publication is at the absolute discretion of BMJ, however they are not peer-reviewed
  • Once published, you will not have the right to remove or edit your response. Removal or editing of responses is at BMJ's absolute discretion
  • If patients could recognise themselves, or anyone else could recognise a patient from your description, please obtain the patient's written consent to publication and send them to the editorial office before submitting your response [Patient consent forms]
  • By submitting this response you are agreeing to our full [Response terms and requirements]

Vertical Tabs

Other responses

Jump to comment:

  • Published on:
    Dexamethasone, survival and neurological impairment
    Dear Editor,

    Professor Pharoah questions whether the increased rate of cerebral palsy among newborn infants who were randomly allocated early postnatal dexamethasone therapy in the trial by Shinwell et al[1] might be because dexamethasone increased survival of infants who were impaired before birth, and not because dexamethasone caused cerebral impairment.

    However, two recent systematic reviews of randomise...

    Show More
    Conflict of Interest:
    None declared.